Associate Professor, Medicine, University of Wisconsin Medical School
Oncology
Dr. Douglas G. McNeel, MD
|
|
Give Review
Douglas G. McNeel, MD is an expert in the field of Oncology. He researched medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10/19 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification". Douglas G. McNeel is a published MD. He published 72 publications, including: 'A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T.' Douglas McNeel accepts Medicare payments and is listed with Medicare.gov.
Publications
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T.
- Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase (PAP) in Patients with Castration-Resistant Prostate Cancer.
- DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.
- Preclinical and clinical development of DNA vaccines for prostate Cancer.
- A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation T...
- A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.
- A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate Cancer.
- ProState carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.
- The androgen receptor: a biologically relevant vaccine target for the treatment of prostate Cancer.
- Human ProState Tumor Antigen-Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade.
- Immunization with a prostate Cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.
- DNA Vaccines for Prostate Cancer.
- Current controversies in the management of biochemical failure in prostate Cancer.
- Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted t-cell epitopes.
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate Cancer.
- T cells localized to the androgen-deprived proState are T(H) 1 and T(H) 17 biased.
- Expression and Immunotherapeutic Targeting of the SSX Family of Cancer-Testis Antigens in Prostate Cancer.
- Vaccines Targeting the Cancer-testis Antigen SSX-2 Elicit HLA-A2 Epitope-specific Cytolytic T Cells.
- Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate Cancer.
- Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory Renal cell carcinoma.
- CD8+ T cells specific for the androgen receptor are common in patients with prostate Cancer and are able to lyse prostate tumor cells.
- Antibody responses to prostate-associated antigens in patients with prostatitis and prostate Cancer.
- IgG responses to Tissue-associated antigens as biomarkers of immunological treatment efficacy.
- Identification of autoantibodies in a patient with testicular Cancer and concurrent inflammatory bowel disease.
- DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate Cancer.
- Prostate Cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.
- Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate Cancer.
- An aberrant proState antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.
- Treatment of chronic lymphocytic Leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
- Potentiating endogenous antitumor immunity to prostate Cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
- Methods for constructing and evaluating antitumor DNA vaccines.
- A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patien...
- Antibody and T-cell responses specific for the androgen receptor in patients with prostate Cancer.
- Inducible expression of a prostate Cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
- Endothelin receptor antagonists in Cancer therapy.
- MAD-CT-2 identified as a novel melanoma Cancer-testis antigen using phage immunoblot analysis.
- Immunotherapy for prostate Cancer - recent progress in clinical trials.
- Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate Cancer a...
- Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.
- Humoral immune responses to testis antigens in sera from patients with prostate Cancer.
- A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate Cancer.
- Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced Malignancies, including an assessment of effect on tumor ...
- Antigen-specific IgG elicited in subjects with prostate Cancer treated with flt3 ligand.
- Newer therapies in advanced prostate Cancer.
- Identification of antigen-specific IgG in sera from patients with chronic prostatitis.
- Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.
- Monitoring regulatory immune responses in tumor immunotherapy clinical trials.
- Hypereosinophilia as a presenting sign of Acute graft-versus-host disease after allogeneic bone marrow transplantation.
- His-tag ELISA for the detection of humoral tumor-specific immunity.
- Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate Cancer.
- Clinical translation of peptide-based vaccine trials: the HER-2/neu model.
- Identification of T helper epitopes from prostatic acid phosphatase.
- Naturally occurring prostate Cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate Cancer.
- Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian Cancer.
- Antibody immunity to prostate Cancer associated antigens can be detected in the serum of patients with prostate Cancer.
- Tumor vaccines for the management of prostate Cancer.
- Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
- Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant ...
- Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids.
- Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
- Immune-based therapies for prostate Cancer.
- Safety and immunological efficacy of a prostate Cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
- Prostate Cancer antigens and vaccines, preclinical developments.
- Identification of autoantibodies elicited in a patient with prostate Cancer presenting as dermatomyositis.
- GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate Cancer.
- Cellular immunotherapies for prostate Cancer.
- Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
- HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
- Prioritization of Cancer antigens: keeping the target in sight.
- DNA vaccines for the treatment of prostate Cancer.
- The SSX family of Cancer-testis antigens as target proteins for tumor therapy.
Schools
University Of ChicagoThe Pritzker School Of Medicine
University Of Wa
Fred Huichnson Cancer Resrch
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- American Enterprise Group
- American Republic
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Preferred Plus POS
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Golden Rule
- Humana
- Medicare MCR
- Thrivent Financial
- United Healthcare
- Universal American
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Washington -
University of Chicago Pritzker School of Medicine
Hospital
-
University of Wisconsin Hospital and Clinics
Drug Facts
| NPI NUMBER | 1104892280 | |
| NPPES Provider LastName | MCNEEL | |
| NPPES Provider FirstName | DOUGLAS | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 176.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104892280 |
| Last Name Of The Provider | MCNEEL |
| First Name Of The Provider | DOUGLAS |
| View All |
Similar Doctors
|
|
Dr. Michael S. Huie, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Hegeman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark R. Albertini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel L. Mulkerin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fotios Asimakopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dustin A. Deming, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danielle B. Bol-De Greve, MD
This Doctor is OpenDoctor Recommended.
|